Motivated by interest in evolutionary-informed therapy scheduling, we investigated the origin and dynamics that underlie the development of therapy resistance of an in vitro model of ALK + NSCLC, the patient-derived NCI-H3122 cell line. Here, ALK is linked to non-small cell lung carcinoma.